Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,369.44
    +201.37 (+0.50%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,288.02
    -48.04 (-0.07%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,540.92
    +10.32 (+0.67%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

AstraZeneca (AZN) Discontinues Brazikumab Development

AstraZeneca AZN announced the discontinuation of studies on its monoclonal antibody targeting IL23, brazikumab. The candidate was being studied for two indications, Crohn’s disease (CD) and ulcerative colitis (UC), under the inflammatory bowel disease (IBD) development program.

A phase IIb/III INTREPID study was evaluating brazikumab for treating CD and a phase II EXPEDITION study for treating UC. The program also included the respective open-label extension studies of the INTREPID and EXPEDITION studies.

AstraZeneca cited evolving competitive landscape and the delayed regulatory timeline of brazikumab as reasons for discontinuing the IBD development program on brazikumab. The company further elaborated that the impact of regulatory delays on brazikumab’s development was irrecoverable due to global events.

In the year so far, shares of AstraZeneca have climbed 7.7% against the industry’s 1.9% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

ADVERTISEMENT

We would like to remind the investors that in 2016, AstraZeneca first entered into a licensing agreement with Allergan, now part of AbbVie ABBV, for the global rights to brazikumab. However, in early 2020, AstraZeneca announced that it will regain the global rights to brazikumab from Allergan (now AbbVie).

The termination of the agreement with Allergan was due to Allergan’s decision to divest brazikumab in connection with its merger with AbbVie. AbbVie was contributing to the ongoing funding of brazikumab studies, but this funding will now end.

AstraZeneca’s another recent pipeline setback was the ALXN1840 program. The company announced that it is discontinuing the ALXN1840 program in Wilson Diseases based on the feedback from regulatory authorities which reviewed data from the phase III FoCus study and two phase II mechanistic studies.

AstraZeneca PLC Price and Consensus

AstraZeneca PLC Price and Consensus
AstraZeneca PLC Price and Consensus

AstraZeneca PLC price-consensus-chart | AstraZeneca PLC Quote

Zacks Rank and Stocks to Consider

AstraZeneca currently has a Zacks Rank #3 (Hold).

A couple of better-ranked stocks in the overall medical sector are Novartis NVS and Akero Therapeutics AKRO, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 90 days, the Zacks Consensus Estimate for Novartis’ 2023 earnings per share has increased from $6.52 to $6.67. In the year so far, shares of Novartis have increased 6.1%.

NVS beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 5.15%.

In the past 90 days, the Zacks Consensus Estimate for Akero Therapeutics’ 2023 loss per share has narrowed from $3.46 to $2.78. In the year so far, shares of Akero Therapeutics have fallen by 18.7%.

AKRO beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 7.96%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

Novartis AG (NVS) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research